Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.263
Neutral
RSI(14)
46.821
Neutral
STOCH(KDJ)(9,3,3)
23.193
Sell
ATR(14)
0.762
Low Volatility
CCI(14)
-122.892
Sell
Williams %R
58.020
Sell
TRIX(12,20)
0.189
Sell
StochRSI(14)
0.000
Sell
Galapagos NV
GLPG33.360USD
-0.020-0.06%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.20BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Galapagos NV
Currency: USD Updated: 2026-02-06Key Insights
Galapagos NV's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 114 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Sell, with the highest price target at 27.33.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Galapagos NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Galapagos NV Highlights
StrengthsRisks
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Fairly Valued
The company’s latest PE is -5.92, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 15.33M shares, decreasing 30.59% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 800.00 shares of this stock.
Analyst Rating
Based on
5
analysts
Sell
Current Rating
27.333
Target Price
-18.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Galapagos NV is 7.60, ranking 94 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 61.93M, representing a year-over-year increase of 12.32%, while its net profit experienced a year-over-year increase of 278.59%.
Score
Financials
5.25
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.01
Operational Efficiency
10.00
Growth Potential
8.39
Shareholder Returns
7.36
Galapagos NV's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Galapagos NV is 8.15, ranking 59 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.92, which is -548.14% below the recent high of 26.51 and -230.79% above the recent low of -19.57.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 114/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Galapagos NV is 4.40, ranking 353 out of 392 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 32.00 and a low of 22.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Sell
Current Rating
27.333
Target Price
-18.11%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Galapagos NV
GLPG
5
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Galapagos NV is 7.09, ranking 105 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 34.90 and the support level at 31.97, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
34.040
Sell
MA10
34.149
Sell
MA20
33.920
Sell
MA50
32.822
Buy
MA100
32.764
Buy
MA200
31.278
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Galapagos NV is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 23.26%, representing a quarter-over-quarter increase of 0.95%. The largest institutional shareholder is David Einhorn, holding a total of 482.75K shares, representing 0.73% of shares outstanding, with 0.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Gilead Sciences Inc
Tang Capital Management, LLC
Madison Avenue Partners LP
EcoR1 Capital, LLC
Columbia Threadneedle Investments (US)
Prosight Capital
Segall Bryant & Hamill, LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Galapagos NV is 7.17, ranking 17 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.26
VaR
+2.89%
240-Day Maximum Drawdown
+20.55%
240-Day Volatility
+35.05%
Return
Best Daily Return
60 days
+2.92%
120 days
+4.85%
5 years
+22.47%
Worst Daily Return
60 days
-3.61%
120 days
-8.61%
5 years
-13.02%
Sharpe Ratio
60 days
+1.46
120 days
+0.38
5 years
-0.41
Risk Assessment
Maximum Drawdown
240 days
+20.55%
3 years
+49.03%
5 years
+71.87%
Return-to-Drawdown Ratio
240 days
+1.25
3 years
-0.08
5 years
-0.16
Skewness
240 days
-0.25
3 years
+0.14
5 years
+1.04
Volatility
Realised Volatility
240 days
+35.05%
5 years
+34.58%
Standardised True Range
240 days
+2.32%
5 years
+3.28%
Downside Risk-Adjusted Return
120 days
+49.54%
240 days
+49.54%
Maximum Daily Upside Volatility
60 days
+14.89%
Maximum Daily Downside Volatility
60 days
+17.99%
Liquidity
Average Turnover Rate
60 days
+0.45%
120 days
+0.50%
5 years
--
Turnover Deviation
20 days
+27.34%
60 days
+41.00%
120 days
+56.39%
Peer Comparison
Biotechnology & Medical Research
Galapagos NV
GLPG
6.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
